Glenmark Pharmaceuticals announced that it has obtained semi-exclusive rights develop and market a generic fluticasone/salmeterol DPI in 15 European countries as part of an agreement with Polish pharmaceutical company Celon Pharma. The countries covered in the deal include the UK, Germany, Norway, Sweden, and Romania. Glenmark will pay an undisclosed amount up front, plus milestone payments and royalties, to Celon.
Glenmark Pharmaceuticals Limited Chairman Glenn Saldanha commented, “The deal reinforces Glenmark’s growing capabilities in the respiratory segment and is a significant step forward towards building a strong respiratory franchise in Europe. We are pleased to collaborate with Celon given their established track record with this inhaler product in Europe.”
Celon Pharma CEO Maciej Wieczorek said “For many years we have invested heavily in developing technologies for inhalation drugs, and this agreement is yet another proof that the direction we have chosen is correct. The common experiences of both companies in the area of manufacturing, commercialization and distribution of inhaled drugs will translate into greater availability of combination therapy in a DPI inhaler in many European countries.”
Read the Glenmark press release.
